Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

GS Nowakowski; DH Yoon; P Mondello; E Joffe; I Fleury; A Peters; Richard Greil; M Ku; R Marks; K Kim; PLL Zinzani; J Trotman; L Sabatelli; D Huang; EE Waltl; M Winderlich; S Ambarkhane; NC Kurukulasuriya; R Cordoba; G Hess; G Salles

doi:10.1182/blood-2021-148302

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

GS Nowakowski, DH Yoon, P Mondello, E Joffe, I Fleury, A Peters, Richard Greil, M Ku, R Marks, K Kim, PLL Zinzani, J Trotman, L Sabatelli, D Huang, EE Waltl, M Winderlich, S Ambarkhane, NC Kurukulasuriya, R Cordoba, G HessG Salles

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

7 Citations (Web of Science)

Original language	English
Journal	BLOOD
Volume	138
DOIs	https://doi.org/10.1182/blood-2021-148302
Publication status	Published - 2021

Access to Document

10.1182/blood-2021-148302

Cite this

Nowakowski, GS., Yoon, DH., Mondello, P., Joffe, E., Fleury, I., Peters, A., Greil, R., Ku, M., Marks, R., Kim, K., Zinzani, PLL., Trotman, J., Sabatelli, L., Huang, D., Waltl, EE., Winderlich, M., Ambarkhane, S., Kurukulasuriya, NC., Cordoba, R., ... Salles, G. (2021). Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. BLOOD , 138. https://doi.org/10.1182/blood-2021-148302

Nowakowski, GS ; Yoon, DH ; Mondello, P et al. / Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. In: BLOOD 2021 ; Vol. 138.

@article{551497f969af4714b381b9b08a768978,

title = "Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",

author = "GS Nowakowski and DH Yoon and P Mondello and E Joffe and I Fleury and A Peters and Richard Greil and M Ku and R Marks and K Kim and PLL Zinzani and J Trotman and L Sabatelli and D Huang and EE Waltl and M Winderlich and S Ambarkhane and NC Kurukulasuriya and R Cordoba and G Hess and G Salles",

year = "2021",

doi = "10.1182/blood-2021-148302",

language = "English",

volume = "138",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

}

Nowakowski, GS, Yoon, DH, Mondello, P, Joffe, E, Fleury, I, Peters, A, Greil, R, Ku, M, Marks, R, Kim, K, Zinzani, PLL, Trotman, J, Sabatelli, L, Huang, D, Waltl, EE, Winderlich, M, Ambarkhane, S, Kurukulasuriya, NC, Cordoba, R, Hess, G & Salles, G 2021, 'Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma', BLOOD , vol. 138. https://doi.org/10.1182/blood-2021-148302

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. / Nowakowski, GS; Yoon, DH; Mondello, P et al.
In: BLOOD , Vol. 138, 2021.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

AU - Nowakowski, GS

AU - Yoon, DH

AU - Mondello, P

AU - Joffe, E

AU - Fleury, I

AU - Peters, A

AU - Greil, Richard

AU - Ku, M

AU - Marks, R

AU - Kim, K

AU - Zinzani, PLL

AU - Trotman, J

AU - Sabatelli, L

AU - Huang, D

AU - Waltl, EE

AU - Winderlich, M

AU - Ambarkhane, S

AU - Kurukulasuriya, NC

AU - Cordoba, R

AU - Hess, G

AU - Salles, G

PY - 2021

Y1 - 2021

U2 - 10.1182/blood-2021-148302

DO - 10.1182/blood-2021-148302

M3 - Abstract (Journal)

SN - 0006-4971

VL - 138

JO - BLOOD

JF - BLOOD

ER -

Nowakowski GS, Yoon DH, Mondello P, Joffe E, Fleury I, Peters A et al. Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. BLOOD . 2021;138. doi: 10.1182/blood-2021-148302